International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

被引：0

作者：

Pablo A. Olivera

Stephane Zuily

Paulo G. Kotze

Veronique Regnault

Sameer Al Awadhi

Peter Bossuyt

Richard B. Gearry

Subrata Ghosh

Taku Kobayashi

Patrick Lacolley

Edouard Louis

Fernando Magro

Siew C. Ng

Alfredo Papa

Tim Raine

Fabio V. Teixeira

David T. Rubin

Silvio Danese

Laurent Peyrin-Biroulet

机构：

[1] Centro de Educación Médica e Investigaciones Clínicas (CEMIC),Gastroenterology Section, Department of Internal Medicine

[2] Centre Hospitalier Régional Universitaire de Nancy,Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases

[3] University of Lorraine,IBD outpatient clinics, Colorectal Surgery Unit

[4] INSERM,Department of Medicine

[5] DCAC,NIHR Biomedical Research Centre

[6] Catholic University of Paraná (PUCPR),Center for Advanced IBD Research and Treatment

[7] Gastroenterology Division,Department of Gastroenterology

[8] Rashid Hospital,Department of Gastroenterology

[9] Dubai Health Authority,Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science

[10] Imelda GI Clinical Research Center,Division of Internal Medicine and Gastroenterology

[11] Imelda General Hospital,Department of Gastroenterology

[12] University of Otago,IBD Center, Department of Gastroenterology

[13] University of Birmingham and University Hospitals NHS Foundation Trust,Department of Biomedical Sciences

[14] Kitasato University,Department of Gastroenterology and INSERM NGERE U1256

[15] Kitasato Institute Hospital,undefined

[16] CHU Liège University Hospital,undefined

[17] Centro Hospitalar São João,undefined

[18] The Chinese University of Hong Kong,undefined

[19] Fondazione Policlinico Universitario “A. Gemelli” IRCCS,undefined

[20] Catholic University of Rome,undefined

[21] Cambridge University Hospitals NHS Foundation Trust,undefined

[22] Gastrosaúde - IBD Clinic,undefined

[23] University of Chicago Medicine,undefined

[24] Inflammatory Bowel Disease Center,undefined

[25] Humanitas Clinical and Research Center - IRCCS,undefined

[26] Humanitas University,undefined

[27] Pieve Emanuele,undefined

[28] University Hospital of Nancy,undefined

[29] University of Lorraine,undefined

来源：

Nature Reviews Gastroenterology & Hepatology | 2021年 / 18卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as ‘fully agree’ or ‘mostly agree’ with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.

引用

页码：857 / 873

页数：16

共 299 条

[21] Tinsley A(2016)Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH J. Thromb. Haemost. 14 1480-1716
[22] Lambin T(2010)Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor Arch. Intern. Med. 170 1710-1251
[23] Faye AS(2003)Review article: inherited thrombophilia in inflammatory bowel disease Am. J. Gastroenterol. 98 1247-635
[24] Colombel J-F(2002)Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease J. Pediatr. Gastroenterol. Nutr. 35 629-1166
[25] Baker A(2011)Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis J. Gastroenterol. 46 1158-409
[26] Young K(2011)Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis Thromb. Res. 128 403-343
[27] Potter J(2007)Mutations in clotting factors and inflammatory bowel disease Am. J. Gastroenterol. 102 338-1454
[28] Madan I(2001)Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease Am. J. Gastroenterol. 96 1448-252
[29] Isene R(2004)Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease Turk. J. Gastroenterol. 15 250-e29
[30] Kappelman MD(2011)Genetic predisposition to thrombophilia in inflammatory bowel disease J. Clin. Gastroenterol. 45 e25-2041

← 1 2 3 4 5 6 7 8 9 10 →